Compounds > quinazolines

Page last updated: 2024-08-21

quinazolines and alogliptin

quinazolines has been researched along with alogliptin in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Scheen, AJ	2
Gerich, J	1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A	1
Gallwitz, B	1
Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K	1
Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM	1
Ishikawa, M; Yamada, Y	1
Bakris, GL; Flynn, C	1
Charbonnel, B; Dejager, S; Schweizer, A	1
Hu, W; Lu, X; Tu, Z; Wang, S; Xie, H; Xu, H; Yang, L; Zeng, L; Zeng, S; Zhang, G; Zhang, X; Zhao, X	1
Tibaldi, JM	1
Athyros, VG; Elisaf, MS; Filippatos, TD	1
Kong, L; Lai, ZW; Li, C; Liu, J; Sun, H; Wen, X	1

Reviews

10 review(s) available for quinazolines and alogliptin

Article	Year
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clinical pharmacokinetics, 2010, Volume: 49, Issue:9 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
DPP-4 inhibitors: what may be the clinical differentiators? Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin	2011
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:6 Topics: Administration, Oral; Animals; Boronic Acids; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Hypoglycemic Agents; Linagliptin; Piperidines; Purines; Quinazolines; Uracil	2011
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes & metabolism, 2012, Volume: 38, Issue:2 Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain	2012
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Current diabetes reviews, 2012, Volume: 8, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature reviews. Nephrology, 2013, Volume: 9, Issue:3 Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hospital practice (1995), 2013, Volume: 41, Issue:2 Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Advances in therapy, 2014, Volume: 31, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss	2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin	2014

Other Studies

4 other study(ies) available for quinazolines and alogliptin

Article	Year
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PloS one, 2011, Volume: 6, Issue:11 Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia	2011
[Therapeutic use and adverse events of incretin-related drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2012
Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. European journal of medicinal chemistry, 2013, Volume: 68 Topics: Animals; Crystallography, X-Ray; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Activation; Inhibitory Concentration 50; Linagliptin; Male; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Piperidines; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Uracil	2013
Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin. European journal of medicinal chemistry, 2014, Aug-18, Volume: 83 Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Humans; Linagliptin; Models, Molecular; Piperidines; Protein Conformation; Purines; Quinazolines; Structure-Activity Relationship; Substrate Specificity; Uracil	2014